№ lp_1_2_50429
File format: docx
Character count: 18728
File size: 69 KB
This document is a consultation report on the development of a new indicator for anticoagulation treatment in patients with atrial fibrillation, potentially suitable for inclusion in the Quality and Outcomes Framework (QOF).
Year:
2022
Region / city:
England
Theme:
Atrial fibrillation, Anticoagulation, Healthcare indicators
Document type:
Consultation report
Organization / institution:
NHS England, NICE
Author:
NHS England
Target audience:
Healthcare professionals, policy makers
Period of validity:
Ongoing development
Approval date:
N/A
Modification date:
N/A
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Note:
Year
Year:
Not specified
Region / city:
Not specified
Subject:
Medical referral for Left Atrial Appendage Closure
Document Type:
Medical referral form
Organization / Institution:
Cooper Structural Heart Disease Program
Author:
Not specified
Target Audience:
Medical professionals
Period of validity:
Not specified
Approval Date:
Not specified
Date of changes:
Not specified
Country:
United Kingdom
Healthcare system:
National Health Service
Clinical area:
Cardiology / Stroke prevention
Condition:
Non-valvular atrial fibrillation
Medication:
Apixaban
Medication class:
Direct oral anticoagulant
Purpose:
Switching existing DOAC therapy to apixaban
Target population:
Adults aged 18 years and over with NVAF
Exclusions:
Patients with contraindications to apixaban or indications other than NVAF
Regulatory references:
NICE recommendations, Summary of Product Characteristics
Type of document:
Clinical procedure
Intended users:
Prescribers and pharmacists
Consultation requirement:
Patient consent and clinician consultation
Monitoring requirements:
Renal function and body weight
Geographical scope:
UK clinical practice
Status of apixaban:
Licensed and available as a generic medicine
Year:
2022
Region / City:
Liverpool, United Kingdom
Subject:
Atrial fibrillation, stroke, smart wearables
Document type:
Research study
Organization / Institution:
University of Liverpool
Authors:
Stephanie L. Harrison, Benjamin J. R. Buckley, Yalin Zheng, Andrew Hill, Thant Hlaing, Ruth Davies, Yutao Guo, Deirdre A. Lane, Gregory Y. H. Lip, Liverpool-Huawei Stroke Study Investigators
Target audience:
Medical researchers, healthcare professionals, cardiologists
Period of validity:
2022-ongoing
Approval date:
30/05/2022
Study ID:
ISRCTN30693819
Year:
2022
Region / city:
England
Topic:
Atrial fibrillation, anticoagulation therapy
Document type:
Indicator guidance
Organization / institution:
NICE
Author:
NICE
Target audience:
Healthcare professionals, general practitioners
Validity period:
Until November 2025
Approval date:
November 2022
Date of changes:
N/A
Source guidance:
NICE’s guideline on atrial fibrillation (2021) recommendations 1.6.3 and 1.6.5
Specification:
CVD-05 indicator, Impact and Investment Fund 2022/23
Exclusions:
People with resolved atrial fibrillation, valvular atrial fibrillation, recorded antiphospholipid syndrome
Note:
Contextual description
Year:
2020
Region / City:
Not specified
Topic:
Stroke risk assessment in Atrial Fibrillation patients
Document Type:
Research Supplementary File
Institution:
Not specified
Author:
Not specified
Target Audience:
Medical professionals, researchers
Period of validity:
Not specified
Approval Date:
Not specified
Date of modifications:
Not specified
Acronym:
ABBRUPT
Organ / Institution:
University of Birmingham
Unit:
Birmingham Clinical Trials Unit (BCTU)
Trial Office:
ABBRUPT Trial Office
Country:
United Kingdom
Regulatory Framework:
UK Data Protection Regulations
Policy Framework:
UK Policy Framework for Health and Social Care Research
Trial Design:
Pragmatic open-label interventional multi-centre two-arm randomised controlled trial with internal pilot and economic evaluation
Objectives:
To compare clinical and cost effectiveness of beta blockers versus amiodarone for new onset atrial fibrillation in intensive care and to conduct cost-effectiveness and cost-utility analyses at 90-day follow-up
Target Population:
Patients aged 16 years and over in intensive care units with new onset atrial fibrillation
Sample Size:
2560 patients
Setting:
At least 60 intensive care units across the UK
Interventions:
Amiodarone versus beta blockers (including bisoprolol, metoprolol, esmolol, propranolol, atenolol, labetalol, carvedilol, landiolol)
Primary Outcome:
90-day mortality
Secondary Outcomes:
Clinical and economic outcomes including ICU and hospital measures
Eligibility Criteria:
Defined inclusion and exclusion criteria for patients with new onset atrial fibrillation in ICU
Data Management:
Contact details retained indefinitely on a BCTU database and subject to written request under UK Data Protection Regulations
Oversight Requirements:
Approval required from relevant Trust or Health Board Management prior to patient consent
Consent Requirements:
Written informed consent and participant information sheet on Trust/Health Board headed paper
Local Governance:
Compliance with Good Clinical Practice and UK Policy Framework for Health and Social Care Research
Year:
2016
Region / city:
United States
Topic:
Clinical performance measures for atrial fibrillation
Document type:
Report
Organization:
American Heart Association
Author:
Steve Dentel, William Lewis
Target audience:
Healthcare professionals, clinicians, cardiologists
Period of validity:
2016
Approval date:
Not specified
Date of revisions:
Not specified
Year:
2015
Region / City:
Global
Topic:
Non-Valvular Atrial Fibrillation, Cardiovascular Disease
Document Type:
Report
Organization:
World Heart Federation
Author:
Murphy A, Banerjee A, Breithardt G, Camm J, Commerford P, Freedman B, Gonzales Hermosillo J, Halperin J, Lau C, Perel P, Xavier D, Wood D, Jouven X, Morillo C
Target Audience:
Health professionals, policy makers, public health authorities
Period of Action:
Not specified
Approval Date:
Not specified
Amendment Date:
Not specified
Year:
2026
Region / City:
Not specified
Topic:
Cardiology, Obesity, Atrial Fibrillation
Document Type:
Research Study
Institution:
Not specified
Author:
Not specified
Target Audience:
Cardiologists, medical researchers, healthcare professionals
Study Population:
Morbidly obese patients with BMI ≥35 kg/m² undergoing AF catheter ablation
Sample Size:
217 patients
Methods:
Retrospective observational study
Primary Outcome:
Composite of recurrent atrial arrhythmias and cardiovascular hospitalizations
Risk Factors Analyzed:
BMI fluctuations, blood pressure, obstructive sleep apnea, hyperlipidemia, tobacco use, alcohol use, diabetes mellitus with HbA1c >6.5%
Follow-up Period:
Mean 2.9 years after ablation
Key Findings:
Only HbA1c >6.5% independently predicted primary outcome; timing of ablation did not affect outcomes
Conclusion:
Optimizing glycemic control is crucial for reducing recurrent atrial arrhythmias and cardiovascular hospitalizations in morbidly obese patients undergoing AF ablation
Year:
2020–2021
Region:
Newham, UK
Theme:
Community health services, Atrial fibrillation, Anticoagulant therapy
Document Type:
Service specification
Organization:
Newham Clinical Commissioning Group (CCG)
Author:
NHS commissioning team
Target audience:
Healthcare providers, community pharmacists, GPs
Period of validity:
1st April 2020 – 31st March 2021
Review date:
Not specified
Scope:
Initiation and counselling of oral anticoagulants for patients with atrial fibrillation
Clinical guidelines referenced:
NICE Guidelines, British Committees of Haematology (BCSH), National Patient Safety Agency (NPSA)
Population covered:
Patients registered with Newham GP practices
Service objectives:
Improve access, patient education, reduce inequalities, enhance quality of care, maintain communication across health professionals
Care pathway:
Acute specialist team initiates therapy, community service manages ongoing care, includes counselling, monitoring, and documentation
Exclusion criteria:
Patients deemed clinically unsafe for outpatient management
Year:
Not specified
Field:
Perioperative medicine
Subject:
New-onset atrial fibrillation and catecholamine vasopressor use after non-cardiac surgery
Document type:
Supplementary tables and figures of a clinical research study
Study population:
Surgical patients receiving catecholamine vasopressors and comparator patients
Sample size:
6000 patients
Comparison groups:
Vasopressor group and comparator group
Variables analyzed:
Demographics, comorbidities, medications, types of surgery, postoperative outcomes
Statistical methods:
Univariate and multivariate logistic regression; propensity score matching; subgroup and interaction analyses
Medical conditions examined:
Atrial fibrillation, stroke, myocardial infarction, heart failure, acute kidney injury
Drugs examined:
Norepinephrine, epinephrine, dopamine, metaraminol
Clinical setting:
Non-cardiac surgery
Abbreviations defined:
AF, CCB, ARB, ACEI, MI, HF, AKI
Year:
2026
Region / city:
International multicenter
Topic:
Cardiology, Hematology
Document type:
Supplementary tables and figures
Institution:
GARFIELD-AF and ORBIT-AF study groups
Authors:
Multi-center registry investigators
Target audience:
Clinicians, researchers
Study period:
2 years follow-up
Data collection:
Patient registries
Patient population:
Adults with atrial fibrillation receiving oral anticoagulants
Measured outcomes:
Incidence of intracranial hemorrhage, baseline characteristics, treatment type, comorbidities, vital signs
Data analysis:
Risk factor association with intracranial hemorrhage
Treatment types:
NOAC, VKA, concomitant antiplatelet therapy
Year:
2026
Region / Country:
Multinational
Subject:
Atrial fibrillation treatment strategies
Document type:
Research supplement
Institution:
Clinical research consortium
Population:
Patients with atrial fibrillation
Sample size:
63,525
Variables analyzed:
Demographics, comorbidities, baseline medications, AF type, clinical outcomes
Treatment strategies:
Rate control, Rhythm control
Follow-up period:
2 years
Outcomes measured:
All-cause mortality, cardiovascular mortality, non-haemorrhagic stroke/SE, major bleeding, heart failure
Statistical methods:
Propensity score weighting, overlap-weighted Cox model
Sensitivity analyses:
Exclusion of new-onset AF, exclusion of primary care diagnoses
Year:
2023
Field:
Cardiac electrophysiology
Document type:
Research supplementary material
Methods:
MATLAB and computational simulations
Models:
Aliev-Panfilov, Courtemanche-Ramirez-Nattel
Authors:
Ravinutala, Aliev, Panfilov, Courtemanche, Aguilar et al.
Audience:
Researchers in cardiac modeling and arrhythmia studies
Data:
Simulated phase singularity formation and lifetimes, parameter distributions, histograms, and probability calculations
Purpose:
Illustration of the inspection paradox effect in rotor lifetime analysis
Software:
MATLAB R2018 and Python-adapted code
Simulation details:
Rectangular 200x200 grids, diffusion coefficient 0.2, varied μ1 and μ2 parameters
Reference studies:
Ten Tusscher and Panfilov 2003, Aliev and Panfilov 1996, Courtemanche et al. 1998, Aguilar et al. 2017
Year:
2023
Region / city:
Canberra
Topic:
Medical guidelines, Patient care
Document type:
Guideline
Organization:
Canberra Health Services
Author:
Not specified
Target audience:
Medical officers, nursing staff
Period of validity:
Not specified
Approval date:
Not specified
Date of amendments:
Not specified
Note:
Year
Year:
Not specified
Region / city:
Not specified
Subject:
Medical referral for Left Atrial Appendage Closure
Document Type:
Medical referral form
Organization / Institution:
Cooper Structural Heart Disease Program
Author:
Not specified
Target Audience:
Medical professionals
Period of validity:
Not specified
Approval Date:
Not specified
Date of changes:
Not specified
Note:
Date
Topic:
Medical appeal letter
Document Type:
Sample letter
Organization / Institution:
Boston Scientific Corporation
Author:
Boston Scientific Corporation
Target Audience:
Healthcare providers, insurance companies
Contextual description:
A sample appeal letter intended for healthcare providers to request reconsideration of insurance coverage for the WATCHMAN FLX™ LAAC Device implant procedure.
Country:
United Kingdom
Healthcare system:
National Health Service
Clinical area:
Cardiology / Stroke prevention
Condition:
Non-valvular atrial fibrillation
Medication:
Apixaban
Medication class:
Direct oral anticoagulant
Purpose:
Switching existing DOAC therapy to apixaban
Target population:
Adults aged 18 years and over with NVAF
Exclusions:
Patients with contraindications to apixaban or indications other than NVAF
Regulatory references:
NICE recommendations, Summary of Product Characteristics
Type of document:
Clinical procedure
Intended users:
Prescribers and pharmacists
Consultation requirement:
Patient consent and clinician consultation
Monitoring requirements:
Renal function and body weight
Geographical scope:
UK clinical practice
Status of apixaban:
Licensed and available as a generic medicine